Contact
searchSearch
HMP Global

Videos

Scott Tagawa, MD
Videos
Addition of 177Lu-PSMA-617 for Patients With Metastatic Hormone-Sensitive Prostate Cancer
10/30/2025
Scott Tagawa, MD
Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with...
Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with...
Scott Tagawa, MD, Weill Cornell...
10/30/2025
Radiopharmaceutical Education Institute
Philip Kuo, MD, PhD, University of Arizona Cancer Center
Videos
Association Between Baseline PSMA Expression and Response to 177Lu-PSMA-617 Among Patients with Metastatic Castration-Resistant Prostate Cancer
11/10/2023
Philip Kuo, MD, PhD
Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...
Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...
Philip Kuo, MD, PhD, shares...
11/10/2023
Oncology
Oliver Sartor, MD, Mayo Clinic
Videos

177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
10/25/2023
Oliver Sartor, MD
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress,...
10/25/2023
Oncology
Oliver Sartor, MD, Mayo Clinic
Videos
Identifying Biomarkers to Predict Resistance to Lutetium-177–PSMA-617
10/11/2023
Oliver Sartor, MD
At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.
At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.
At the 2023 EANM meeting, Oliver...
10/11/2023
Oncology

Advancing Oncology Through Radiopharmaceutical Science and Innovation

The Radiopharmaceutical Education Institute (RPEI) will bridge the gap between research, clinical application, and patient care by delivering accessible, multidisciplinary expert insights and education on radiopharmaceuticals in oncology to our engaged national audience of oncologists, oncology advanced practitioners, oncology nurses, diagnostic radiologists, and nuclear medicine specialists.

The Oncology Learning Network and RPEI are also the official digital platforms for our Great Debates & Updates: Solid Tumor live meeting.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use